Schrödinger: The Nvidia Biotech Partner Jensen Huang Told To “Think Bigger”
Schrödinger (NASDAQ: $SDGR) uses quantum mechanics to design new medicines and materials. All top 20 pharmaceutical companies buy its software. Schrodinger’s SEC filings and website claim that the top 20 pharmaceutical companies by revenue are all customers. Many startups pay it royalties and equity in deals worth tens of millions to access its platform. The Eli Lilly acquisition of Morphic Therapeutics Inc. resulted in $47.6 million to Schrödinger. The Takeda Pharmaceutical Co. Ltd. acquisition of a Nimbus Therapeutics subsidiary resulted in $111 million to Schrödinger.
Schrödinger is also a key AI winner. It benefits from falling GPU chip costs, a Nobel-winning prediction model from Google DeepMind that opens up new targets for drug discovery clients, and the enhancement of the company’s physics engine with machine learning.
